Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab ± chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma
ChiCTR2000040196Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Affiliated Cancer Hospital of Shantou University Medical College. Primary endpoint: Overall survival. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000040196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040196.